The aim of this study was to investigate the on‐treatment kinetics of quantitative HBsAg
during entecavir therapy to predict the treatment period needed to achieve functional cure …

Objectives To assess off-treatment virological relapse rates and to determine the role of
hepatitis B surface antigen (HBsAg) quantification in predicting virological relapse after …

Background/purpose The study compared the hepatitis B surface antigen (HBsAg) changes
between hepatitis B e antigen (HBeAg)-negative non-cirrhotic chronic hepatitis B patients …

Background/purpose The predictors of off-therapy response in patients treated with
neucleos (t) ide analogue (NA) have not been elucidated. It remained unexplored whether …

Background & Aims This study investigated whether serum level of hepatitis B surface
antigen (HBsAg) at the end of entecavir treatment was associated with risk of relapse …

Methods This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years,
mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; …

Results Twenty-eight patients were treated for a median period of 21 months (range: 18 to
24 mo). Serum HBsAg level showed a mean of 4.0, 3.7, and 3.6 log 10 IU/mL at …

Background & Aims We investigated the rate of relapse of hepatitis B virus (HBV) infection
after entecavir therapy for chronic hepatitis B and the association between level of hepatitis …

Background & Aims Factors predicting HBsAg seroclearance after treatment cessation,
irrespective of nucleos (t) ide analogue (NA) resumption, have important clinical …

Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti‐
HBc) in patients with chronic hepatitis B receiving first‐line nucleos (t) ide analogues is …